C4 Therapeutics
CCCC
113 hedge funds and large institutions have $1.54B invested in C4 Therapeutics in 2021 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 53 increasing their positions, 20 reducing their positions, and 12 closing their positions.
165% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 20
58% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 12
28% more capital invested
Capital invested by funds: $1.21B → $1.54B (+$334M)
6% more funds holding
Funds holding: 107 → 113 (+6)
2.76% less ownership
Funds ownership: 73.95% → 71.19% (-2.8%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22.8M |
| 2 |
BlackRock
New York
|
+$22.5M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$18.6M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$17.7M |
| 5 |
RI
RTW Investments
New York
|
+$14.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$13.4M |
| 2 |
MS
Maven Securities
St Helier,
Jersey
|
-$8.96M |
| 3 |
LCM
Laurion Capital Management
New York
|
-$6.55M |
| 4 |
MS
Mizuho Securities
Tokyo,
Japan
|
-$6.41M |
| 5 |
PCM
Pinz Capital Management
New York
|
-$6.18M |
CCCC Hedge Fund Activity: Q3 2021 in Review
113 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q3 2021, worth a combined $1.54B — up 28% from $1.21B a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new CCCC positions and 12 closed out — a net gain of 7 holders — while 53 added to existing stakes and 20 trimmed.
The largest buyer was Vanguard Group, adding an estimated $22.8M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $13.4M sold.
- 113 institutional investors held C4 Therapeutics (CCCC) as of Q3 2021, up from 107 in Q2 2021.
- Funds reported $1.54B of C4 Therapeutics stock for Q3 2021, up 28% quarter-over-quarter.
- 19 funds opened new C4 Therapeutics positions in Q3 2021 and 12 closed out, a net change of +7 holders.
- The largest C4 Therapeutics buyer in Q3 2021 was Vanguard Group, an estimated $22.8M added.
- The largest C4 Therapeutics seller in Q3 2021 was Cormorant Asset Management, an estimated $13.4M sold.
Based on aggregated 13F filings for Q3 2021.